Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE FLT3 inhibition in the setting of minimal residual disease and a new immune system via allogeneic transplantation offers a promise of improved survival for these patients. 31550496 2020
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE Consolidation chemotherapy maintained a relatively favorable outcome (3-year CIR, 29%; 3-year RFS, 71%) in patients with intermediate cytogenetics, negative FLT3-ITD, and MRD negativity. 30773106 2019
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE This novel MRD assay is specific and 2 orders of magnitude more sensitive than currently available polymerase chain reaction- or next-generation sequencing-based <i>FLT3-</i>ITD assays. 29643105 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 AlteredExpression phenotype BEFREE CD135 overexpression was a negative predictor of complete remission and of postinduction minimal residual disease at days 14 and 28 (P < .001). 29907544 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE Although novel FLT3 inhibitors are being developed, studies into mechanisms of resistance raise hope of new strategies to prevent emergence of resistance and eliminate minimal residual disease. 28673395 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE The use of inhibitors against FLT3 and TGFβ1 may become a useful strategy for eradicating MRD in MLL+ALL. 28917156 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE The discovery of targetable molecular abnormalities and recent studies of targeted therapies (gemtuzumab ozagomycin, FLT3 inhibitors, isocitrate dehydrogenase inhibitors, and epigenetic therapies), future use of checkpoint inhibitors and other immune therapies such as chimeric antigen receptor T-cells, and maintenance strategies based on the minimal residual disease evaluation represent novel, exciting clinical leads aimed to improve AML outcomes in the near future. 28109402 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE We analyzed the outcome of allo-SCT in a population of FLT3-positive AML patients according to molecular MRD at the pretransplantation workup, assessed by the quantitative expression evaluation of the panleukemic marker Wilms' tumor (WT1) gene. 28159598 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE Our results suggest that ITD-AR levels and molecular MRD should be considered in planning clinical management of FLT3-ITD patients. 27416911 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE On multivariate analysis, independent factors influencing the risk of relapse were detectable morphological disease and FLT3 MRD by PCR pre-transplant. 28052408 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 GeneticVariation phenotype BEFREE We evaluated the feasibility of NGS with high coverage (up to 2.4.10(6) PE fragments) for MRD monitoring on FLT3 ITD. 26078355 2015
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE To develop an assay for clinical molecular diagnostics laboratories to monitor MRD in FLT3/ITD AMLs. 26446915 2015
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 GeneticVariation phenotype BEFREE Although pretreatment covariates such as cytogenetics, monosomal karyotype, relapsed or refractory rather than newly diagnosed AML, and FLT3 internal tandem duplication were associated with relapse, their prognostic effect was much lower once MRD and response were taken into account, the univariable statistical effect of which was not materially affected by inclusion of pretreatment covariates. 25732155 2015
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE UDS appears as a valuable tool for FLT3 mutational screening and for the assessment of minimal residual disease (MRD) during follow-up, by detecting small ITD+ clones that may survive chemotherapy, evolve over time and definitely worsen the prognosis of CN-AML patients. 26384303 2015
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 GeneticVariation phenotype BEFREE We report the application of a new technique, tandem duplication PCR (TD-PCR), for detecting MRD in FLT3/ITD AML patients. 25240816 2014
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 GeneticVariation phenotype BEFREE Modern risk factors include KIT and/or FLT3 gene mutations and minimal residual disease (MRD) levels, but their respective values have never been prospectively assessed. 23321257 2013
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE Our method could be applied to 97% of FLT3-ITD-positive patients and was as sensitive as other MRD parameters such as PML-RARA , NPM1 mutations, or MLL -PTD (correlation: r = 0.63; 0.99, and 0.99, respectively). 22458420 2012
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 GeneticVariation phenotype BEFREE Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. 22454318 2012
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE Therefore, FLT3-ITD is not a reliable marker for minimal residual disease in acute myeloid leukemia. 22532519 2012
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE Most sensitive methodology to detect MRD is molecular polymerase chain reaction (PCR) but its applicability is restricted to AML with leukemia-specific molecular targets (e.g.AML1-ETO, CBFB-MYH11, MLL, FLT-3). 22196957 2012
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 AlteredExpression phenotype BEFREE Furthermore, we found that FLT3-ITD MRD levels after induction chemotherapy are predictive of complete remission duration. 22129478 2012
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 GeneticVariation phenotype BEFREE Such an approach redefined cytogenetic/genetic categories in 2 groups: (1) low-risk, including good/intermediate K-MRD(-) with 4-year RFS and OS of 58% and 73%, respectively; and (2) high risk, including poor-risk K, FLT3-ITD mutated cases, good/intermediate K-MRD(+) categories, with RFS and OS of 22% and 17%, respectively (P < .001 for all comparisons). 20548095 2010
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE Multivariate analysis allowing for age, karyotype, FLT3-internal tandem duplications and white blood cell count at diagnosis showed that MRD after the first course of chemotherapy was an independent prognostic factor. 20668473 2010
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 AlteredExpression phenotype BEFREE This study shows that it could be possible to study the efficacy of FLT3 inhibitors using the level of minimal residual disease as a short-term end-point. 19042917 2009
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.100 Biomarker phenotype BEFREE Studying FLT3/ITD kinetics in minimal residual disease setting may provide some answers for the changes we observed. 16642044 2006